GLP-1 Agonists as Longevity Drugs
GLP-1 receptor agonists (semaglutide, tirzepatide, orforglipron) expanding from diabetes/obesity into cardiovascular, kidney, Alzheimer's, and longevity applications. EVOKE trial for Alzheimer's pending. First oral non-peptide GLP-1 approved.
Watching
Novo Nordisk EVOKE/EVOKE+ trial results for semaglutide in Alzheimer's expected 2026. If positive, GLP-1 enters third blockbuster category (neurodegeneration) and transforms the longevity drug landscape.
Tracked Metrics
Signals
Timeline
Real-world retrospective cohort study (J Diabetes Complications, May 2026) using TriNetX electronic health records compares tirzepatide vs semaglutide in 290,606 semaglutide and 44,471 tirzepatide…
A 27-author Nature paper (Liskiewicz, Novikoff et al, 10.1038/s41586-026-10427-5) describes a unimolecular quintuple agonist combining GLP-1R + GIPR co-agonism with the PPARα/γ/δ small-molecule…
Phase 2b double-blind RCT (108 participants, 32 weeks) in adults with HIV on stable ART and BMI ≥25 shows semaglutide significantly slows biological aging across four independent epigenetic clocks:…
ASSESSMENT UPDATE (April 2026): GLP-1 agonists have crossed from observational signal to RCT-level evidence for biological aging. A Phase 2b double-blind RCT showed semaglutide significantly…
ASSESSMENT: GLP-1 agonists are emerging as the most pragmatic path to longevity therapeutics — not by design, but by accumulated evidence. With 10M+ patients already treated, observational data shows…
A JAMA review of 1.65 million diabetic patients on GLP-1 receptor agonists (semaglutide and peers) reports sharply lower incidence of several cancers versus non-GLP-1 controls: pancreatic -59%, liver…
FDA approves orforglipron (Eli Lilly) — first oral non-peptide GLP-1 agonist. $150/month, no injections, no cold chain. Lilly pre-manufactured $1.5B inventory for simultaneous multi-country launch.
FDA approved Eli Lilly's orforglipron (Foundayo) on April 1, 2026 — the first oral GLP-1 receptor agonist for weight loss that can be taken any time of day without food or water restrictions.…
Umbrella review of 60 meta-analyses: GLP-1 RAs reduce dementia risk -45%, serious infections down, fractures -33%, respiratory disease -15%. Thyroid disease risk +28%. First systematic assessment of…
Endocrine Connections (Mar 2026) models semaglutide's impact on life expectancy using SELECT trial data applied to a UK real-world population (overweight/obesity + established CVD, no T2DM).…
Study of 600K+ patients: GLP-1 users show lower rates of addiction syndromes (alcohol, nicotine, narcotics), overdoses, and substance-related deaths. Mechanism: GLP-1 modulates brain reward circuitry…
Retrospective propensity-matched cohort on the TriNetX network (mostly US healthcare orgs) compared tirzepatide and semaglutide initiators among adults with type 2 diabetes for incident…
AAOS presentation: 147K patients, GLP-1 use associated with osteoporosis +30%, gout +12%, osteomalacia +150% over 5 years. Contradicts umbrella review showing fracture -33%. Discrepancy unresolved —…
ACHIEVE-3 head-to-head trial (1,700 patients, 52 weeks): orforglipron beats oral semaglutide ~2:1 on weight loss (8.9 kg vs 5 kg) and HbA1c (2.2% vs 1.4%). Dropout higher for orforglipron (9.7% vs…
Meta-analysis of 24 randomized controlled trials (40,694 participants) in Metabolism (Feb 2026) finds GLP-1 receptor agonists and co-agonists (including dual and triple) reduce atrial fibrillation…
Am J Physiol Heart Circ Physiol (Feb 2026): 183 metformin-treated T2DM patients followed for 12 months. Liraglutide + empagliflozin combination achieved the greatest carotid intima-media thickness…
FDA concludes GLP-1 agonists not linked to suicidal behavior. Meta-analysis of 91 trials (107,910 patients) + Sentinel data (1.16M patients 2015-2023). Ordered removal of suicide risk warnings from…
Novo Nordisk EVOKE and EVOKE+ trials: first large-scale Alzheimer's RCTs with semaglutide. Target: 20% reduction in cognitive decline. High-risk bet — if positive, GLP-1 enters third blockbuster…